While there are other weight loss plans available that prescribe compounded GLP-1 injections, Hers offers access to a more comprehensive approach. If prescribed medicine through Hers, you’ll ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth highflier indicated it may soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...

Business has been booming for the company, a multispecialty telehealth platform, with rapid growth in its weight loss offering, including compounded GLP-1 injection products. Hims & Hers expects ...

Hims & Hers’ weight loss offerings will now mainly include its oral medications and the liraglutide injection, which the company plans to launch in the early second half of 2025. Also ...

Ozempic also has a notable effect on weight loss. One study comparing a weekly semaglutide injection to a placebo ... For weight loss, Hers offers access to a type of metformin called metformin ...

The shares tumbled 26% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection ... Hims & Hers said it expects it weight loss offering ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth highflier indicated it may soon stop offering some compounded versions of weight-loss drugs ... grappled with a shortage of ...

Hims & Hers Health (HIMS) shares nosedive on news ... And remember, these are the blockbuster diabetes and weight loss drugs that are new and really popular. Uh, patients still say they're in ...